HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PAT-1102

a histone deacetylase inhibitor; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - PAT-1102: 1
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - PAT-1102: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - PAT-1102: 1

Experts

1.	Annamalai, Pazhanimuthu: 1 article (01/2015)
2.	Gavara, Govindarajulu: 1 article (01/2015)
3.	Hiriyan, Jagadheshan: 1 article (01/2015)
4.	Natesan, Selvakumar: 1 article (01/2015)
5.	Sambasivam, Ganesh: 1 article (01/2015)
6.	Shivarudraiah, Prasad: 1 article (01/2015)
7.	Sukumaran, Sunil K: 1 article (01/2015)

Related Diseases

1.

Neoplasms (Cancer)

01/01/2015 - "PAT-1102 demonstrated potent HDAC-inhibitory activity and growth-inhibitory properties against a panel of cancer cell lines. "
01/01/2015 - "Based on the pre-clinical efficacy and safety profile of PAT-1102, the compound demonstrates significant potential for evaluation as a novel drug candidate for cancer therapy."
01/01/2015 - "Our results indicate that PAT-1102 is a novel, potent, orally available HDAC inhibitor with antiproliferative activity against several human cancer cell lines and antitumor activity in mouse xenograft models. "
01/01/2015 - "Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models."

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors

Related Therapies and Procedures

1.	Therapeutics